Palantir Gains Unlimited Access to NHS Data: What Lessons for Businesses Using AI?

A Deal That Redefines the Rules of the Game for AI in Healthcare

In May 2025, Palantir Technologies secured what has been described as "unlimited" access to data from 67 million British patients through the NHS. This £480 million ten-year contract positions the American company at the heart of Europe's largest public healthcare system. Palantir's Federated Data Platform (FDP) will centralize medical records, hospital data, and primary care information.

For SME and mid-market leaders in France and Belgium, this agreement goes beyond a simple tech news story. It illustrates a fundamental trend: access to massive datasets is becoming a decisive competitive advantage for companies deploying artificial intelligence. However, this concentration raises essential questions about regulatory compliance, data sovereignty, and sector-specific opportunities.

This article analyzes the concrete implications of the Palantir-NHS agreement for your AI strategy: what it reveals about market evolution, GDPR risks to anticipate, and opportunities for French and Belgian companies working in healthcare or handling sensitive data.

How the Palantir-NHS Deal Changes the European AI Market

Contract Terms and Their Scope

The contract grants Palantir centralized management of NHS England's data. Specifically, the Federated Data Platform enables the aggregation of information from multiple sources: hospitals, general practitioners, pharmacies, mental health services. The stated objective is to improve care coordination and reduce waiting lists that have reached 7.5 million patients in the UK.

Several elements of the contract concern European observers:

• Exceptional duration: ten years of partnership, compared to the usual three to five years for this type of public contract
• De facto exclusivity: Palantir becomes the sole provider of NHS England's data infrastructure
• Raw data access: while Palantir claims not to "own" the data, its algorithms can analyze and cross-reference it
• Commercial exploitation: the NHS explicitly authorizes use of the platform to develop commercially viable AI products

Market and Regulatory Reactions

The Information Commissioner's Office (ICO), the British equivalent of France's CNIL, has demanded additional guarantees on data pseudonymization. The British Medical Association has expressed reservations about patient consent. Meanwhile, Palantir's stock rose 12% in the days following the announcement, with investors betting on the model's replicability in other countries.

For the European market, the signal is clear: American tech giants are accelerating their positioning on public health data. This dynamic creates competitive pressure on local players and raises questions about regulatory reciprocity between the EU and post-Brexit UK.

GDPR Compliance: What SMEs/Mid-Market Companies Must Monitor

European Legal Framework Facing Data Transfers

GDPR imposes strict obligations for any personal data processing, particularly health data classified as "sensitive" (Article 9). French and Belgian companies collaborating with British or American partners must now factor in several parameters.

Since Brexit, the UK benefits from an adequacy decision from the European Commission, renewable every four years. This decision could be questioned if British practices diverge too far from European standards. The Palantir-NHS agreement will be scrutinized as a test of this compatibility.

Key vigilance points for companies:

• Standard contractual clauses: verify that your contracts with subprocessors include the new clauses adopted by the Commission in 2021
• Data Protection Impact Assessment (DPIA): mandatory for any large-scale health data processing
• Processing register: precisely document data flows to third countries
• Right to object: provide mechanisms allowing individuals to oppose AI algorithm processing of their data

Specific Risks Related to Generative AI

At AISOS, we observe that many SMEs use generative AI tools without measuring the data protection implications. ChatGPT, Claude, or Gemini can process customer information that transits through American servers. The Palantir-NHS agreement reminds us that even the most important public institutions accept these transatlantic transfers.

For SMEs or mid-market companies, the risk is not theoretical. France's CNIL imposed €147 million in fines in 2024, with 35% concerning violations related to international data transfers. Sanctions now affect companies of all sizes, not just Big Tech.

Practical recommendations:

• Audit data flows to your AI tools and their subprocessors
• Prioritize European-hosted solutions when they exist
• Train your teams on best practices for AI tool input (never enter personal data)
• Document your technical choices to demonstrate due diligence in case of inspection

Customer Data Management: Rethinking Your Infrastructure

Data Centralization: A Double-Edged Model

The Palantir model relies on centralization: aggregating all data sources into a single platform to maximize analytical value. This approach appeals to large organizations seeking to break down silos. It also carries vulnerabilities.

For SMEs or mid-market companies, excessive centralization creates three risks:

• Single point of failure: a cyberattack or outage affects all operations
• Vendor lock-in: migrating to another solution becomes exponentially costly
• Expanded attack surface: the more you centralize, the more you attract attackers

The alternative involves adopting a "data mesh" architecture where data remains distributed but interoperable. This approach, more complex to implement, offers better resilience and facilitates GDPR compliance through decentralized governance.

Building Competitive Advantage with Your Proprietary Data

The Palantir-NHS agreement confirms an economic reality: quality structured data constitutes the most valuable asset for training and deploying high-performing AI models. SMEs and mid-market companies that possess unique sector-specific data have an underexploited strategic advantage.

Concrete examples:

• A medical testing laboratory with 15 years of history can develop predictive models inaccessible to new entrants
• A B2B distributor with detailed order data can optimize its supply chain better than competitors
• A consulting firm with thousands of documented missions can create proprietary decision-support tools

The first step involves mapping your data assets: what data do you collect, for how long, with what granularity? This mapping often reveals unexpected value opportunities.

Sector Opportunities: Healthcare as a B2B AI Laboratory

The French AI Healthcare Market

Healthcare represents 12% of French GDP, or €290 billion annually. AI is advancing rapidly: medical imaging, diagnostic assistance, care pathway optimization, hospital management. The French AI healthcare market will reach €2.1 billion in 2027, according to Xerfi projections.

French SMEs and mid-market companies hold strong positions in several niches:

• Medical imaging: Therapixel, Owkin, Incepto develop automated reading solutions
• Hospital management: Maincare, Softway Medical, Dedalus France offer integrated platforms
• Patient pathways: Doctolib, Qare, Livi transform healthcare access
• Clinical research: Quinten, Oncodesign accelerate drug development

The Palantir-NHS agreement could paradoxically benefit these players. The data sovereignty debates it raises strengthen the commercial argument for European solutions among French and Belgian healthcare establishments.

Entry Strategies for Non-Healthcare SMEs

Healthcare AI lessons apply to other regulated sectors: finance, insurance, energy, transport. SMEs and mid-market companies that master compliance and sensitive data management can transpose these skills.

Three positioning approaches:

• Partnership with healthcare players: offer technology building blocks (cybersecurity, hosting, integration) to specialized publishers
• Progressive diversification: adapt your existing solutions to healthcare sector-specific constraints
• HDS certification: obtain health data hosting certification to become an eligible partner for public establishments

HDS (Health Data Hosting) certification constitutes a significant but surmountable entry barrier. It demonstrates to potential clients your ability to manage sensitive data according to the most demanding standards.

Preparing Your Company for 2025-2026 Regulatory Changes

The European AI Act Comes into Effect

The European regulation on artificial intelligence (AI Act) imposes new obligations on companies that develop or deploy AI systems. High-risk systems, a category that includes healthcare, employment, and financial services, must meet transparency, documentation, and human oversight requirements.

Implementation timeline:

• February 2025: prohibition of AI systems presenting unacceptable risks
• August 2025: obligations for general-purpose AI models (like GPT-4)
• August 2026: complete obligations for high-risk systems

SMEs and mid-market companies that anticipate these deadlines gain a competitive advantage. Documenting your AI systems, assessing their risks, and implementing appropriate governance takes time. Starting now avoids last-minute rushing.

Building Robust Data Governance

AISOS audits reveal that 73% of French SMEs lack formalized data governance policies. This gap becomes critical with multiplying regulations and increasing AI adoption.

Effective data governance rests on four pillars:

• Inventory: knowing what data you possess, where it's stored, who accesses it
• Classification: distinguishing public, internal, confidential, and sensitive data
• Policy: defining rules for collection, retention, sharing, and deletion
• Control: regularly verifying rule application and correcting gaps

This governance is not just a regulatory constraint. It constitutes the essential foundation for exploiting your data with AI reliably and reproducibly.

Conclusion: Transforming Regulatory Constraints into Competitive Advantage

The Palantir-NHS agreement crystallizes tensions between technological innovation and personal data protection. For French and Belgian SMEs and mid-market companies, it offers several actionable insights.

First, proprietary data is becoming a major strategic asset. Companies that structure and leverage their customer data possess an advantage that tech giants cannot easily replicate.

Second, regulatory compliance, far from being a brake, can become a commercial argument. Faced with legitimate concerns about data sovereignty, European solutions compliant with GDPR and the AI Act are gaining attractiveness.

Third, the healthcare sector illustrates a trend that will progressively affect all sectors. Companies that develop skills in sensitive data management and responsible AI today will be better positioned tomorrow.

To assess your positioning and identify opportunities specific to your sector, an audit of your visibility in AI search engines constitutes a concrete first step. AISOS supports SMEs and mid-market companies in this approach, from initial analysis to recommendation implementation.